Brain Tumors

Tailored Therapy in Diffuse Gliomas

We review the current data regarding the prognostic and predictive value of IDH mutation and 1p/19q codeletion in gliomas. We also discuss possible management algorithms using these biomarkers to tailor surgical and adjuvant therapy for specific diffuse gliomas.

Brain Tumors

Depressive symptoms and impaired executive functioning, both common in patients with glioblastoma, are independently associated with shorter overall survival.

A core set of symptoms are common across brain tumor patients and underscore the complexity of brain tumors and their management.

New research suggests that characterizing low-grade gliomas according to molecular markers may be a more useful approach in order to guide treatment decisions.

The immunotherapeutic rindopepimut with bevacizumab yielded a significant survival improvement in relapsed glioblastoma patients with a EGFRvIII mutation.

A phase I trial of an oncolytic polio/rhinovirus vaccine was safe and showed promising efficacy in patients with recurrent glioblastoma.

Treating newly diagnosed glioblastoma with “tumor treating fields” is a safe and effective therapeutic option, according to a new trial.

The addition of procarbazine, CCNU, and vincristine to RT in patients with low-grade glioma prolongs progression-free and overall survival vs RT alone.


Subscribe to Brain Tumors on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.